Synairgen Regulatory News (SNG)

4 Sep 2009 07:00



Synairgen plc

('Synairgen' or the 'Company')

Directorate changes 

Southampton, UK - 4 September 2009: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company with a particular focus on viral defence in asthma and COPD, is pleased to announce the appointment of Phillip David Monk and Paul Hugh Anthony Clegg to the Board on 3 September 2009. 

Dr Phillip Monk, aged 40, has joined the Board as Chief Scientific Officer. Phillip joined Synairgen in October 2006 as Head of Bioscience Development. Phillip was previously Director of the Respiratory and Inflammation Biology group at Cambridge Antibody Technology ('CAT') and led the scientific development of CAT-354, an anti-IL-13 antibody being developed for the treatment of severe asthma. Prior to joining CAT, he worked at Bayer AG within the respiratory disease therapeutic area, focusing on the development of novel therapies for asthma, COPD and cystic fibrosis. He has options over 139,439 ordinary shares of 1p each in the Company, equating to 0.23% of the Company's issued share capital. 

Paul Clegg, aged 49, has joined the Board as a non-executive director. Paul was previously Managing Director and Chief Executive Officer of Cowen International Limited and director of Cowen Asset Management Limited until June 2008 and is currently Chief Executive Officer of Accsys Technologies PLC and a director of Clegg Enterprises Limited. Paul brings over twenty years' senior investment banking experience, recently with a particular focus on biotechnology, to the Company. He has a beneficial interest of 147,058 ordinary shares of 1p each in the Company, equating to 0.25% of the Company's issued share capital. 

The Company also announces that, due to relocation, Susan Sundstrom has resigned from her role as a non-executive director of the Company effective on 3 September 2009 to pursue other interests. 

In accordance with the AIM Rules for Companies, the Company confirms that there is no further disclosure obligation required, pursuant to Rule 17, Schedule Two, Paragraph (g).

Simon Shaw, Chairman of Synairgen, commented, 

"I am delighted to welcome Phill and Paul to the Board, which will benefit significantly from their distinct areas of expertise and experience. I also thank Sue on behalf of the Board for her significant contribution to Synairgen's development since its foundation in 2003".

Ends

For further information, please contact: